Leukemia experts recommend asciminib (SCEMBLIX) as an option for adults with newly diagnosed Ph+ CML in chronic phase*
A Ph+ CML diagnosis may feel overwhelming. Your first treatment is an important decision in your CML journey. Only SCEMBLIX has been tested head-to-head against all commonly used medications (tyrosine kinase inhibitors, or TKIs*) for newly diagnosed adults to fight Ph+ CML in chronic phase.
SCEMBLIX is a good option for many patients, including those newly diagnosed. Ask your doctor if SCEMBLIX could be a good fit for you.
SEE THE RESULTS
How SCEMBLIX compared to commonly used TKIs.†
BECOME MORE INFORMED
about Ph+ CML in chronic phase and take an active role in your leukemia journey.
HEAR FROM SCEMBLIX PATIENTS
who have Ph+ CML in chronic phase.
EXPLORE FINANCIAL SUPPORT OPTIONS
If eligible, you could pay as little as $0 with the Co-Pay plus offer‡
Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 3, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org ↗. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
†SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel ® (dasatinib), and Bosulif ® (bosutinib). Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.
‡Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state healthcare program, (ii) where patient is not using insurance coverage at all, (iii) where the patient’s insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient’s insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.